Oxana V Makarova-Rusher1, Sean F Altekruse2, Tim S McNeel3, Susanna Ulahannan1, Austin G Duffy1, Barry I Graubard4, Tim F Greten1, Katherine A McGlynn4. 1. Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 2. Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 3. Information Management Services Inc, Calverton, Maryland. 4. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) incidence has been increasing in the United States for several decades; and, as the incidence of hepatitis C virus (HCV) infection declines and the prevalence of metabolic disorders rises, the proportion of HCC attributable to various risk factors may be changing. METHODS: Data from the Surveillance, Epidemiology, and End Results-Medicare linkage were used to calculate population attributable fractions (PAFs) for each risk factor over time. Patients with HCC (n = 10,708) who were diagnosed during the years 2000 through 2011 were compared with a 5% random sample of cancer-free controls (n = 332,107) residing in the Surveillance, Epidemiology, and End Results areas. Adjusted odds ratios (ORs) and PAFs were calculated for HCV, hepatitis B virus (HBV), metabolic disorders, alcohol-related disorders, smoking, and genetic disorders. RESULTS: Overall, the PAF was greatest for metabolic disorders (32%), followed by HCV (20.5%), alcohol (13.4%), smoking (9%), HBV (4.3%), and genetic disorders (1.5%). The PAF for all factors combined was 59.5%. PAFs differed by race/ethnicity and sex. Metabolic disorders had the largest PAF among Hispanics (PAF, 39.3%; 95% confidence interval [CI], 31.9%-46.7%) and whites (PAF, 34.8%; 95% CI, 33.1%-36.5%), whereas HCV had the largest PAF among blacks (PAF, 36.1%; 95% CI, 31.8%-40.4%) and Asians (PAF, 29.7%; 95% CI, 25.9%-33.4%). Between 2000 and 2011, the PAF of metabolic disorders increased from 25.8% (95% CI, 22.8%-28.9%) to 36% (95% CI, 33.6%-38.5%). In contrast, the PAFs of alcohol-related disorders and HCV remained stable. CONCLUSIONS: Among US Medicare recipients, metabolic disorders contribute more to the burden of HCC than any other risk factor, and the fraction of HCC caused by metabolic disorders has increased in the last decade. Cancer 2016;122:1757-65. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND:Hepatocellular carcinoma (HCC) incidence has been increasing in the United States for several decades; and, as the incidence of hepatitis C virus (HCV) infection declines and the prevalence of metabolic disorders rises, the proportion of HCC attributable to various risk factors may be changing. METHODS: Data from the Surveillance, Epidemiology, and End Results-Medicare linkage were used to calculate population attributable fractions (PAFs) for each risk factor over time. Patients with HCC (n = 10,708) who were diagnosed during the years 2000 through 2011 were compared with a 5% random sample of cancer-free controls (n = 332,107) residing in the Surveillance, Epidemiology, and End Results areas. Adjusted odds ratios (ORs) and PAFs were calculated for HCV, hepatitis B virus (HBV), metabolic disorders, alcohol-related disorders, smoking, and genetic disorders. RESULTS: Overall, the PAF was greatest for metabolic disorders (32%), followed by HCV (20.5%), alcohol (13.4%), smoking (9%), HBV (4.3%), and genetic disorders (1.5%). The PAF for all factors combined was 59.5%. PAFs differed by race/ethnicity and sex. Metabolic disorders had the largest PAF among Hispanics (PAF, 39.3%; 95% confidence interval [CI], 31.9%-46.7%) and whites (PAF, 34.8%; 95% CI, 33.1%-36.5%), whereas HCV had the largest PAF among blacks (PAF, 36.1%; 95% CI, 31.8%-40.4%) and Asians (PAF, 29.7%; 95% CI, 25.9%-33.4%). Between 2000 and 2011, the PAF of metabolic disorders increased from 25.8% (95% CI, 22.8%-28.9%) to 36% (95% CI, 33.6%-38.5%). In contrast, the PAFs of alcohol-related disorders and HCV remained stable. CONCLUSIONS: Among US Medicare recipients, metabolic disorders contribute more to the burden of HCC than any other risk factor, and the fraction of HCC caused by metabolic disorders has increased in the last decade. Cancer 2016;122:1757-65. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
Entities:
Keywords:
attributable fractions; hepatitis B virus; hepatitis C virus; hepatocellular carcinoma; metabolic disorders; population
Authors: Geraldine M McQuillan; Deanna Kruszon-Moran; Benny J Kottiri; Lester R Curtin; Jacqueline W Lucas; Raynard S Kington Journal: Am J Public Health Date: 2004-11 Impact factor: 9.308
Authors: Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian Journal: Cancer Res Date: 2014-06-01 Impact factor: 12.701
Authors: Tania M Welzel; Barry I Graubard; Stefan Zeuzem; Hashem B El-Serag; Jessica A Davila; Katherine A McGlynn Journal: Hepatology Date: 2011-06-30 Impact factor: 17.425
Authors: Paulo S Pinheiro; Karen E Callahan; Francis P Boscoe; Raymond R Balise; Taylor R Cobb; David J Lee; Erin Kobetz Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-07-19 Impact factor: 4.254
Authors: Wanshui Yang; Jing Sui; Yanan Ma; Tracey G Simon; Jessica L Petrick; Michelle Lai; Katherine A McGlynn; Peter T Campbell; Edward L Giovannucci; Andrew T Chan; Xuehong Zhang Journal: Clin Gastroenterol Hepatol Date: 2020-01-09 Impact factor: 11.382
Authors: Jian Zheng; Deborah Kuk; Mithat Gönen; Vinod P Balachandran; T Peter Kingham; Peter J Allen; Michael I D'Angelica; William R Jarnagin; Ronald P DeMatteo Journal: Ann Surg Oncol Date: 2016-12-05 Impact factor: 5.344
Authors: Yi Shen; Harvey Risch; Lingeng Lu; Xiaomei Ma; Melinda L Irwin; Joseph K Lim; Tamar Taddei; Karen Pawlish; Antoinette Stroup; Robert Brown; Zhanwei Wang; Wei Jia; Linda Wong; Susan T Mayne; Herbert Yu Journal: Cancer Causes Control Date: 2020-02-14 Impact factor: 2.506
Authors: Meheret Endeshaw; Benjamin D Hallowell; Hilda Razzaghi; Virginia Senkomago; Matthew T McKenna; Mona Saraiya Journal: Cancer Date: 2018-11-27 Impact factor: 6.860
Authors: Lawrence S Engel; Emily C Zabor; Jaya Satagopan; Anders Widell; Nathaniel Rothman; Thomas R O'Brien; Mingdong Zhang; Stephen K Van Den Eeden; Tom K Grimsrud Journal: Int J Cancer Date: 2019-02-14 Impact factor: 7.396